.jpg)
Features
September 5, 2023
NLA Responds to the USPSTF Recommendation Statement on Screening Lipid Panel in Children and Adolescents
The United States Preventive Services Task Force (USPSTF) recently released its Final Recommendation Statement on...
Read More...July 13, 2023
Novartis Receives FDA Approval for Label Update On Use of Leqvio (Inclisiran)
Novartis received FDA approval for a label update that will allow for use of Leqvio ® (inclisiran) in certain patients...
Read More...June 3, 2023
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Lifestyle habits can have a profound impact on atherosclerotic cardiovascular disease (ASCVD) risk. The National...
Read More...February 27, 2023
NLA and ASPC Release Joint Clinical Perspective
The National Lipid Association (NLA) and the American Society for Preventive Cardiology (ASPC) have released a joint...
Read More...October 17, 2022
The NLA Announces its 2023 Educational Plan
The NLA has developed a series of educational activities and engagement opportunities for our members and those...
Read More...